



/David Webster/

MAIL STOP - PCT
Docket No.: 27579U

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: ROSCHER, et al. Art Unit: XX
Appl. No.: 10/589,871 Examiner: XX
Appl. Filing Date: August 18, 2006 Confirm. No.: XX
Intl. Appl. No.: PCT/EP2005/050799
Intl. Appl. Filing Date: February 25, 2005
For: **CICLESONIDE AND GLYCOPYRRONIUM COMBINATION**

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

1. Information Disclosure Statement; and
2. PTO Form-1449 with 48 references cited, and copies of 34 of the 48 references cited.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

November 22, 2006


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le



MAIL STOP - PCT
Docket No.: 27579U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: ROSCHER, et al. Art Unit: XX
Appl. No.: 10/589,871 Examiner: XX
Appl. Filing Date: August 18, 2006 Confirm. No.: XX
Intl. Appl. No.: PCT/EP2005/050799
Intl. Appl. Filing Date: February 25, 2005
For: **CICLESONIDE AND GLYCOPYRRONIUM COMBINATION**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. ☒ [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. ☐ [] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

☐ [] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

☐ [] ii. a check in the amount required by 37 C.F.R. 1.17(p).

- c. [] The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
- [] Certification report(e) below; and
- [] a check in the amount as required by 1.17(p).
- d. [] The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.
- e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
- [] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
- or
- [] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- or
- [] Appropriate certification is attached.
- f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [~~XX~~] Copies of the documents are attached herewith with a completed PTO Form-1449.

or

[] Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or


[XXX] Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

November 22, 2006


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le

PTO FORM-1449

**INFORMATION DISCLOSURE
CITATION**

Inventor: ROSCHER, et al.


Appl. No.:
10/589,871Intl. Appl. No:
PCT/EP2005/050799Art Unit:
XXAppl. Filing
Date:
August 18, 2006Intl. Appl. Filing
Date:
February 25, 2005Examiner:
XX
Confirm. No:
XX**U. S. PATENT DOCUMENTS**

Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
/D.W./	A1	2005/0026886	2/3/2005	Meade et al.	7/15/2004
/D.W./	A2	2005/0175548	8/11/2005	Goede et al.	2/7/2005
/D.W./	A3	6,302,331	10/16/2001	Dvorsky et al.	4/20/2000
/D.W./	A4	6,645,466	11/11/2003	Keller et al.	11/10/1999
/D.W./	A5	6,204,285	3/20/2001	Fabiano et al.	6/27/1997
/D.W./	A6	6,454,193	9/24/2002	Busick et al.	4/20/2000
/D.W./	A7	6,397,838	6/4/2002	Zimlich Jr. et al.	12/21/1999
/D.W./	A8	5,263,475 (corresp. to EP0505321)	11/23/1993	Altermatt et al.	3/18/1992
/D.W./	A9	2004/0266869 (corresp. to WO0247668)	12/30/2004	Montague et al.	12/12/2001
/D.W./	A10	5,482,934 (corresp. to DE4129535)	1/9/1996	Calatayud et al.	7/20/1994
/D.W./	A11	5,733,901 (corresp. to WO9422899)	3/31/1998	Gutterer	3/31/1994
/D.W./	A12	6,307,060 (corresp. to WO9821183)	10/23/2001	Noe et al.	5/11/1999
/D.W./	A13	6,455,524 (corresp. to WO0069468)	9/24/2002	Bozung et al.	5/9/2000
/D.W./	A14	6,475,467 (corresp. to WO0007567)	11/5/2002	Keller et al.	8/2/1999

FOREIGN PATENT DOCUMENTS

Exam. Initial		Document No.	Public. Date	Country	Translation
/D.W./	A15	02/36106 A2	5/10/2002	WO	Abstract
/D.W./	A16	0 725 725 B1	8/14/1996	EP	N/A
/D.W./	A17	02/083113 A2	10/24/2002	WO	N/A
/D.W./	A18	0 505 321 A2	9/23/1992	EP	No
/D.W./	A19	02/47668 A2	6/20/2002	WO	Abstract
/D.W./	A20	247,680	2/25/1926	GB	N/A
/D.W./	A21	41 29 535 A1	3/12/1992	DE	No
/D.W./	A22	2006/003078 A1	1/12/2006	WO	N/A
/D.W./	A23	95/02650 A1	1/26/1995	WO	N/A
/D.W./	A24	94/22899 A1	10/13/1994	WO	Abstract
/D.W./	A25	91/11495 A1	8/8/1991	WO	Abstract
/D.W./	A26	93/11743 A1	6/24/1993	WO	N/A
/D.W./	A27	91/14422 A1	10/3/1991	WO	N/A
/D.W./	A28	91/04011 A1	4/4/1991	WO	N/A
/D.W./	A29	91/11173 A1	8/8/1991	WO	N/A
/D.W./	A30	98/52542 A1	11/26/1998	WO	N/A
/D.W./	A31	0 553 298 B1	8/4/1993	EP	N/A
/D.W./	A32	0 372 777 B1	6/13/1990	EP	N/A
/D.W./	A33	98/00133 A1	1/8/1998	WO	N/A
/D.W./	A34	98/21183 A1	5/22/1998	WO	Abstract
/D.W./	A35	98/00132 A1	1/8/1998	WO	N/A
/D.W./	A36	01/76575 A2	10/18/2001	WO	N/A
/D.W./	A37	02/30394 A2	4/18/2002	WO	N/A
/D.W./	A38	0 407 028 B2	1/9/1991	EP	N/A
/D.W./	A39	0 691 865 B1	1/17/1996	EP	N/A
/D.W./	A40	0 650 410 B1	5/3/1995	EP	N/A

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./



/D.W./	A41	00/69468 A1	11/23/2006	WO	Abstract
/D.W./	A42	92/11190 A2	7/9/1992	WO	N/A
/D.W./	A43	96/32150 A1	10/17/1996	WO	N/A
/D.W./	A44	00/07567 A1	2/17/2000	WO	Abstract
/D.W./	A45				

OTHER

Exam. Initial	(Including Author, Title, Date, Pertinent Pages, etc.)				
/D.W./	A46	Mirakhur, R.K., et al., "Glycopyrrolate: pharmacology and clinical use", <u>Anaesthesia</u> , Vol. 38, pg. 1195-1204, (1983).			
/D.W./	A47	Levin, R.M., et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder", <u>The Journal of Urology</u> , Vol. 128, pg. 396-398, (1982).			
/D.W./	A48	Cooke, R.D., "Glycopyrrolate in bladder dysfunction", <u>SA Medical Journal</u> , Vol. 63, pg. 3, (1983).			
/D.W./	A49	Demian, J., et al., "High-Performance Liquid Chromatographic Separation of 3-[(Cyclopentylhydroxyphenyl-acetyl)oxy]-1,1-Dimethyl-pyrrolidinium Bromide Diastereomers", <u>Journal of Liquid Chromatography</u> , Vol. 13, No. 4, pg. 779-787, (1990).			

Examiner	Date Considered
/David Webster/	2/10/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.